Glenzocimab for REperfusion in the Setting of Endovascular Therapy for Brain infarctioN: GREEN Study

Summary

Emergent reperfusion is the main goal for acute ischemic stroke therapy (AIS). Endovascular therapy (EVT) is recommended within 6 hrs of stroke onset, and up to 24 hrs following perfusion imaging criteria. Despite the major benefit associated with MT, more than 50% of the patients remain disabled at 3 months. Reperfusion rates after MT are critical to determine functional outcome. However, complete reperfusion is obtained in only 50 % of the patients, due to, at least in part, erratic emboli and/or no-reflow processes. The aim of this study is to evaluate the efficacy of glenzocimab in addition to EVT and compared to EVT plus placebo, whether or not associated with ntravenous thrombolysis (IVT), on functional outcome at day 90.

Timeline

Start

2023-01-03

Primary completion

2025-07-30

Completion

2025-07-30

Publications

• Mazighi M, Lambert J, Gory B, Seners P, Calviere L, Cho TH, Aghetti A, Pasi M, Boulouis G, Lapergue B, Consoli A, Turc G, Rouchaud A, Wolff V, Pop R, Suissa L, Richard S, Cordonnier C, Arquizan C, Costalat V, Guedon A, Cognard C, Mameri L, Escalard S, Redjem H, Smajda S, Robichon E, Al Raaisi A, Boisseau W, Blanc R, Maier B, Boursin P, Dubus E, Desilles JP, Piotin M, Rigon MR, Olivot JM. Glenzocimab for reperfusion in the setting of endovascular therapy for brain infarction: GREEN study. J Neurointerv Surg. 2026 May 14;18(6):1539-1544. doi: 10.1136/jnis-2025-023606.

Drugs

Indications